Endo Int'l Reports Top-line Results From Phase 2 Study Of CCH For Adhesive Capsulitis Of Shoulder

RTTNews | 1204天前
Endo Int'l Reports Top-line Results From Phase 2 Study Of CCH For Adhesive Capsulitis Of Shoulder

(RTTNews) - Pharmaceutical company Endo International plc (ENDP) announced Friday top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder."

The Phase 2 study participants receiving up to three doses of CCH showed some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit.

The difference compared to those study participants receiving placebo was not statistically significant.

The safety profile of CCH in the Phase 2 study was consistent with the known safety profile from other studies.

The Phase 2 trial enrolled 198 participants with unilateral idiopathic AC of the shoulder with restricted range of motion (ROM) and function in the affected shoulder. Participants were randomized 1:1 to receive CCH or placebo administered by ultrasound-guided injection.

read more
Endo Intl's Par Pharma Recalls Treprostinil Injection For Silicone Particulates

Endo Intl's Par Pharma Recalls Treprostinil Injection For Silicone Particulates

Dublin, Ireland -based Endo International plc announced that its operating company Par Pharmaceutical, Inc. is recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The recall, being conducted along with the U.S. Food and Drug Administration, is due to the potential for the presence of silicone particulates in the product solution.
RTTNews | 583天前
Endo International Says Health Canada Approves XCOPRI To Treat Epilepsy

Endo International Says Health Canada Approves XCOPRI To Treat Epilepsy

Specialty pharmaceutical company Endo International plc (ENDPQ.PK) announced Thursday that its operating company Paladin Labs, Inc. (PLB.TO) has received Health Canada's approval of XCOPRI (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
RTTNews | 841天前
Swiss Market Ends Modestly Lower

Swiss Market Ends Modestly Lower

The Switzerland market ended weak on Friday, in line with markets across Europe, as concerns about the health of U.S. regional banks hurt sentiment and triggered a sell-off in financials stocks across the globe.
RTTNews | 3小時32分鐘前
TSX Down Sharply; Materials Stocks Tumble

TSX Down Sharply; Materials Stocks Tumble

The Canadian market is down sharply in negative territory Friday afternoon due to a sell-off in materials stocks. Concerns about growth after Bank of Canada Governor Tiff Maclem warned that spillovers from U.S. President Donald Trump's tariff policies could weaken the economy.
RTTNews | 4小時32分鐘前
Bay Street Headed For Weak Start

Bay Street Headed For Weak Start

Lower Canadian and U.S. futures amid worries about the health of US regional banks, and lingering concerns about U.S.-China trade tensions point to a weak start for the Canadian market on Friday.
RTTNews | 8小時48分鐘前
FTSE 100 Down 1.4%; Bank Stocks Fall On U.S. Lenders' Credit Woes

FTSE 100 Down 1.4%; Bank Stocks Fall On U.S. Lenders' Credit Woes

The UK market is down sharply on Friday, hurt by a sell-off in the financials sector amid concerns about the health of U.S. banks after a couple of regional banks disclosed that they were exposed to alleged fraud by borrowers, spreading jitters about credit market turmoil.
RTTNews | 10小時9分鐘前